Our current aAPC-based products include ex vivo adoptive cellular therapy and direct in vivo injection of an aAPC therapeutic in cancer.

NexImmune’s lead clinical programs are an adoptive cellular therapy to treat AML, MDS and Multiple Myeloma patients. AIM 101 is a direct injectable aAPC cocktail that is being developed to represent a precisely manufactured pharmaceutical product.

Product Pipeline

ABOUT AML: There is an increasing unmet need in AML due to growing incidence, lack of new treatment options and an aging population. It is estimated that >70% of these patients have a poor outcome. Of the estimated 19,520 new patients in the US, only approximately 45% of these patients receive a hematopoetic stem cell transplant (SCT). While transplant offers benefit, more than half of these patients will have a relapse of their leukemia. For high risk patients, the one year mortality rate is 90%. There are no new treatment options available for patients with relapsed AML following SCT treatment or that had been transplant ineligible.

ABOUT MM: Multiple Myeloma accounts for about 10% - 15% of all hematologic malignancies and primarily affects older individuals, with approximately 30,770 new cases. Though significant progress has been made for the treatment of myeloma patients extending survival beyond 7 years, the vast majority, however, relapse requiring further treatment. Similar to activities demonstrated by adoptive cellular therapies in other cancers, T-cell based treatments have the potential to shift the paradigm in myeloma.

ABOUT AIM ACT: AIMTM adoptive cellular therapy (AIM ACT) is a mutli-tumor associated antigen T cell product. PBMCs from a donor or the patient are used to enrich and expand tumor specific CD8+ T cells using NexImmune’s proprietary AIM system. The clinical trials for NEXI-001 and NEXI-002 will start enrolling in Q1 2020.

ABOUT AIM 101: AIM 101 is a PLGA-PEG based nanoparticle decorated with HLA presenting disease-relevant antigens and humanized stimulatory ligands. To enhance engagement with targeted T cell subtypes, aAPCs can be designed to increase trafficking to lymph nodes. AIM 1010 is an ideal application for rapid loading and delivery of known tumor associated antigens of choice or neoantigens corresponding to individual patients.